52346 Federal Register / Vol. 75, No. 164 / Wednesday, August 25, 2010 / Notices 

students, faculty members, and 

competency exam takers; and a Webbased survey of community college faculty. 

ESTIMATED ANNUALIZED BURDEN TABLE

Forms Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average burden hours per 

response 

Total burden 

hours 

Web-based student baseline survey Students enrolled in workforce program 1,350 1 20/60 450 

Focus groups with students .............. Students enrolled in workforce program 256 1 1.5 384 

Focus groups with faculty ................. Instructors from workforce program 50 1 1.5 75 

Focus groups with exam takers ........ Competency exam takers not enrolled in workforce program 32 1 1.5 48 

Web-based faculty survey ................ Instructors from workforce program 300 1 10/60 50 

Total ........................................... ........................................................... ........................ ........................ ........................ 1,007 

Seleda Perryman, 

Office of the Secretary, Paperwork Reduction 

Act Clearance Officer. 

[FR Doc. 2010–21070 Filed 8–24–10; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Scientific Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

and the Assistant Secretary for Health 

have taken final action in the following 

case: 

Elizabeth Goodwin, PhD, University of 

Wisconsin-Madison: Based on the report 

of an investigation conducted by the 

University of Wisconsin-Madison (UWM) and additional analysis conducted 

by ORI in its oversight review, the U.S. 

Public Health Service (PHS) found that 

Elizabeth Goodwin, PhD, former 

associate professor of genetics and 

medical genetics, UW-M, engaged in 

scientific misconduct while her research 

was supported by National Institute of 

General Medical Sciences (NIGMS), 

National Institutes of Health (NIH), 

grants R01 GM051836 and R01 

GM073183. 

PHS found that the Respondent 

engaged in misconduct in science by 

falsifying and fabricating data that she 

included in grant applications 2 R01 

GM051836–13 and 1 R01 GM073183– 

01. 

PHS found that in grant application 

2 R01 GM051836–13, Respondent 

knowingly and intentionally: 

• Falsified Figures 5A and 5B by 

reusing figures from two of her earlier 

published papers and falsely labeling 

them to claim results that had not been 

achieved in her laboratory. 

• Falsified Figure 7B by reusing a 

figure from one of her published papers 

and both relabeling it to claim she had 

detected the STAR–2 protein rather than 

the TRA-l protein actually detected and 

modifying the image in the application 

to disguise its origin. 

• Falsified Figure 8C by using a figure 

produced by one of her students and 

relabeled it to show that RNAi treatment 

of C. elegans led to increased expression 

of the TRA–2 protein when this result 

had not been obtained by the student. 

• Falsified the table on Page 20 of the 

application showing phenotypic 

frequencies of worms expressing star-2 

(ok483) mutants by significantly 

overstating the level of aberrant 

phenotypes and fabricating certain 

categories of phenotypes not seen by the 

student conducting the research. 

PHS finds that in grant application 

1 R01 GM073183–01, Dr. Goodwin 

knowingly and intentionally: 

• Falsified Figure 5 because she used 

the same two lanes in both Figure 5 and 

Figure 7, although they were flipped 

horizontally in one of the figures to 

disguise their reuse. In Figure 7, the 

lanes illustrated an effect on laf-1 during 

developmental stages of C. elegans, and 

in Figure 5, the same lanes purportedly 

illustrated an effect on laf-1 noncoding 

RNA. A witness testified that the result 

in Figure 5 had not been observed, 

while that in Figure 7 had, indicating 

that the claims for Figure 5 were 

falsified. 

• Falsified Figure 8 by reusing 

photographs prepared by a student that 

identified the location of rRas-l 

expression in adult worms and claiming 

instead that the images illustrated the 

location of laf-1 mRNA. The images had 

been enlarged and cropped to disguise 

their location. 

Dr. Goodwin has entered into a 

Voluntary Exclusion Agreement in 

which she has voluntarily agreed, for a 

period of three (3) years, beginning on 

July 22, 2010: 

(1) To exclude herself from any 

contracting or subcontracting with any 

agency of the U.S. Government and from 

eligibility for, or involvement in, 

nonprocurement programs of the U.S. 

Government referred to as ‘‘covered 

transactions’’ pursuant to the HHS 

Implementation of OMB Guidelines to 

Agencies on Governmentwide 

Debarment and Suspension at 2 CFR 

376, et seq.; and 

(2) To exclude herself from serving in 

any advisory capacity to PHS, including 

but not limited to service on any PHS 

advisory committee, board, and/or peer 

review committee, or as a consultant. 

This Agreement is entered into 

pursuant to the terms of a plea 

agreement by and between the 

Respondent and the United States 

Attorney for the Western District of 

Wisconsin. 

FOR FURTHER INFORMATION CONTACT: 

Director, Division of Investigative 

Oversight, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8800. 

John Dahlberg, 

Director, Division of Investigative Oversight, 

Office of Research Integrity. 

[FR Doc. 2010–21048 Filed 8–24–10; 8:45 am] 

BILLING CODE 4150–31–P 


srobinson on DSKHWCL6B1PROD with NOTICES